Status:
COMPLETED
An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This will be a single centre study conducted at the 3rd hospital affiliated to Peking University. Approximately 24 healthy Chinese volunteers, male and female, will be recruited to obtain at least 20 ...
Eligibility Criteria
Inclusion
- Chinese ethnicity defined as having both parents and 4 grandparents who are Chinese
- Have a normal Body size and weigh at least 50 kg
Exclusion
- History of diseases or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs determined by the investigator
- Current and/or past history of intolerance or hypersensitivity to drugs with a similar chemical structure or mechanism of action to AZD6140 or any ingredient in its formulation
- Symptoms of any clinically significant illness within 2 weeks of screening
- A personal or family history of bleeding diatheses or a reasonable suspicion of vascular abnormalities including aneurysms
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00721448
Start Date
June 1 2008
End Date
August 1 2008
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, China